Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection
- PDF / 231,998 Bytes
- 4 Pages / 595.276 x 790.866 pts Page_size
- 78 Downloads / 203 Views
www.virosin.org www.springer.com/12250
(0123456789().,-volV)(0123456789().,-volV)
LETTER
Clinical Characteristics of Hospitalized Patients with SARS-CoV-2 and Hepatitis B Virus Co-infection Xiaoping Chen1 • Qunqun Jiang1 • Zhiyong Ma1 • Jiaxin Ling2 • Wenjia Hu1 • Qian Cao1 • Pingzheng Mo1 Lei Yao3 • Rongrong Yang1 • Shicheng Gao1 • Xien Gui1 • Wei Hou3 • Yong Xiong1 • Jinlin Li4 • Yongxi Zhang1
•
Received: 17 May 2020 / Accepted: 13 July 2020 Ó Wuhan Institute of Virology, CAS 2020
Dear Editor, Coronavirus disease 2019 (COVID-19) is a global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 infection was first detected in Wuhan, China in late December 2019. The virus was spreading rapidly to other cities of China and accumulating cases had been reported (Li et al. 2020). On March 11, 2020, WHO declared the outbreak of SARSCoV-2 as a pandemic. As of June 28, around 10 million COVID-19 cases have been reported in 216 countries or territories and the worldwide death toll has passed 490,000 according to data from WHO (https://www.who.int/emer gencies/diseases/novel-coronavirus-2019). Until now, there is no effective drug or vaccine available against SARSCov-2 infection. In addition to the recent emerged SARS-CoV-2, hepatitis B virus (HBV) is one of the viruses which cause a
Xiaoping Chen, Qunqun Jiang and Zhiyong Ma contributed equally to this work.
Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12250-020-00276-5) contains supplementary material, which is available to authorized users. & Yongxi Zhang [email protected]
global infection and threat public health. In worldwide, the prevalence of HBsAg is about 3.9% (Polaris Observatory 2018). According to a nationwide epidemiological survey of population whose ages range from 1 to 59 years in China, 2006, the prevalence of HBsAg was 7.2% (Liang et al. 2009). As SARS-CoV-2 and HBV both can cause liver damage (Fan et al. 2020), further understanding of the risk of SARS-CoV-2 on patients with HBV infection is urgently required in order to design an optimized treatment strategy. However, the impacts of SARS-CoV-2 infection on HBV patients are still not clear. For example, we do not yet know whether the SARS-CoV-2 infection is more severe in HBV patients and we also do not have much knowledge about the impact of SARS-CoV-2 on the course of HBV infection. In this retrospective study, we investigated the clinical characterizes of the patients coinfected with SARS-CoV-2 and HBV by analyzing the clinical records and laboratory tests of 123 COVID-19 patients admitted to Zhongnan Hospital of Wuhan University, Wuhan, China, from January 5 to February 20, 2020. A total of 123 patients with COVID-19 were enrolled in this study, including 50 males and 73 females. The median age of total enrolled patients was 51.0 years (IQR, 35.0–66.0; range, 20–96 years). The most common 3
State Key Laboratory of Virology/Institute of Medical Virology/Hubei Province Key Laboratory of Allergy and Immunolo
Data Loading...
